Bio-Rad Laboratories did not just talk about digital PCR; it expanded it with Vericheck ddPCR kits built for the QX700 system, aiming squarely at quality control in cell and gene therapy workflows. Investors who held Bio-Rad Laboratories from the start of the year are up 21.2%, including dividends. If you had been deciding on 1 January, what would you have needed to believe about ddPCR adoption and pricing pressure to justify buying before any of this news arrived?
The move put Bio-Rad Laboratories in the middle of this trade. Scan 34 healthcare AI stocks for other companies exposed to it.
The Two Futures Investors Debated For Bio-Rad Laboratories
The shares cost US$303 at the start, and anyone looking at Bio-Rad Laboratories had to decide which story about digital PCR and diagnostics felt more realistic.
The bullish narrative pointed to a Fair Value of US$437, a price those expectations implied if things went right. This view was built on ddPCR gaining share and revenue rising 3.7% a year, with profit margins settling at 7.7%.
The bearish view anchored on a Fair Value of US$265. It reflected concerns that tighter pricing controls, 1.9% annual revenue growth, and profit margins of 8.2% would leave the stock overextended at the prevailing quote.
What The Evidence Around Bio-Rad Laboratories Actually Tested
Bio-Rad Laboratories leaned into the bullish story as Q2 2026 arrived, with stronger than expected Q2 2025 performance, the Stilla Technologies acquisition, and higher 2025 guidance tied directly to ddPCR and diagnostics. At the same time, measured results showed revenue at US$651.6m in Q2 2025 and US$651m in Q2 2026, while net income and net margin both rose. Overall, the evidence cut both ways.
The lesson is clear. When a thesis hangs on premium technology gaining share, as with Bio-Rad's ddPCR push, track two things in every report: whether segment sales actually expand and whether net margin moves toward or away from the original forecast.
What You Are Paying For In Bio-Rad Laboratories Today
Bio-Rad Laboratories now trades at US$370 from the start of the year, with this Narrative’s Fair Value sitting below that level based on its own assumptions. The focus is on ddPCR platforms, consumables and process chromatography to support recurring revenue and operating leverage.
Anyone paying today effectively assumes that ddPCR demand, consumables growth and buybacks together can offset soft instrument orders and funding risks. The question is how the selected Narrative’s concerns about weak hardware demand and pressure on public research budgets affect that bet.
"Persistent softness in instrument demand, particularly in the biotech and global academic research markets, is creating headwinds for revenue growth and leading to lower manufacturing absorption, as evidenced by the year-over-year declines and management commentary; if this trend continues, it may stagnate revenue and put downward pressure on gross and operating margins over the long term."
That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for
Looking Past Bio-Rad’s Lab Bench
Bio-Rad Laboratories keeps attention on precision diagnostics and complex therapies. That focus raises a nearby question.
When more patients receive advanced treatments, demand does not stop at the vial. People still need surgery, monitoring and long term care.
Another health care giant concentrates on those touchpoints. It develops medicines for difficult conditions and devices that make procedures possible.
As higher complexity care spreads, reliance on broad treatment platforms can matter more. That wider footprint could reshape how you track this theme.
That argument has a Narrative and a number behind it. → See the company one Narrative values 21% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com